Notice to Annual General Meeting in STENOCARE A/S

STENOCARE A/S convenes its Annual General Meeting on April 29, 2026 at 10:30 AM CEST in Copenhagen (doors open 10:00) at Lund Elmer Sandager Law Firm. Agenda items are the appointment of a meeting chairman, the chairman's report, and presentation/resolution on the audited annual report; this is a routine corporate governance notice with no material financial guidance or operational updates.

Analysis

An upcoming AGM on a small-cap healthcare issuer is a concentrated governance catalyst: the audited annual report and any board-level votes can change perceived solvency and strategic optionality within days. For a low-float name, a qualified audit opinion, confirmation of a ‘‘going concern’’ or disclosure of material related‑party transactions typically elicits 30–50% moves within a 1–8 week window as forced sellers and margin providers react.

Second-order effects matter: suppliers (CROs, raw-material vendors), distributors and any lenders facing covenant tests will re-price exposure or demand security if the report signals weak cash flow — this can accelerate contract terminations or trigger clawbacks within 30–90 days and potentially shift value to acquirers or better-capitalized competitors. Also expect liquidity to evaporate intraday; small changes in supply of available stock (single large holder selling or a large buy) will amplify price action and create short-term arbitrage opportunities.

Risk/catalyst framing: tail risk is a rapid dilutive capital raise or out-of-court restructuring if auditors highlight solvency issues; that reverses only if a credible capital injection or definitive sale process is announced (likely 2–12 weeks to execute). The contrarian angle is that markets often overshoot on governance noise — if the annual report contains only accounting conservatism without structural cash-flow impairment, a 20–40% repricing back toward peers can occur over 1–3 months once management lays out a remediation plan.

Key Decisions for Investors

• Short STENO (ticker: STENO) via borrow or CFD into the AGM event window (initiate 0–10 days pre‑AGM). Set a hard stop at +30% and a take‑profit band at 30–50% downside; target asymmetric payoff if the annual report contains going‑concern language or related‑party red flags — position size limited to ≤1% NAV due to borrow/illiquidity risk.
• Buy contingent long: place limit order to accumulate STENO on a confirmed post‑AGM sell‑off that meets both (a) >30% intraday drop and (b) no qualified audit opinion. Scale in over 2–6 weeks with a 6–12 month horizon; upside re‑rating scenario = 30–100% if management secures financing or a buyer.
• If options are available, buy 3–6 month STENO puts 15–25% OTM to hedge event risk for directional long exposure elsewhere in the portfolio (cost = insurance premium). Alternatively, for a lower cost directional short, sell a covered call against a small purchased stake to monetize implied volatility if you hold a tactical long.
• Pair trade for sector-neutral exposure: short STENO and go long a liquid Nordic healthcare name (proxy hedge e.g., NVO — Novo Nordisk) sized to neutralize beta for a 1–3 month event trade. This isolates idiosyncratic governance risk while keeping broader pharma exposure intact; expect win if STENO is re-rated independently of sector moves.